Evidence map›Paper›PMID 34896646›Full record

Trial reportThe journal of pain2022

Characterization of Patients With and Without Painful Peripheral Neuropathy After Receiving Neurotoxic Chemotherapy: Traditional Quantitative Sensory Testing vs C-Fiber and Aδ-Fiber Selective Diode Laser Stimulation.

Mikhail I Nemenov, Harutyun Alaverdyan, Carrie Burk, Kristen Roles, Karen Frey, Yan Yan, Gene Kazinets, Simon Haroutounian

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in The journal of pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03687970 (A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03687970 nacompletednot on this map

A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN): a Feasibility Study

TypeinterventionalSponsorWashington University School of MedicineRan2018 to 2019Enrolled42ConditionsChemotherapy-induced Peripheral NeuropathyArmsBrief Pain Inventory, Hospital Anxiety and Depression Scale, Neuropathic Pain Symptom Inventory, Diode Laser fiber type Selective Stimulator, Quantitative sensory testing
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mikhail I NemenovLasMed, Mountain View, California; Department of Anesthesiology, Stanford University, Stanford, California.
Harutyun AlaverdyanDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri.
Carrie BurkDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri.
Kristen RolesDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri.
Karen FreyDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri.
Yan YanDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Gene KazinetsLasMed, Mountain View, California.
Simon HaroutounianDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: sharout@wustl.edu.
Washington University in St. Louis · USLasmed (United States) · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPNR43CA206796 · NCI · LASMED, LLC · PI NEMENOV, MIKHAIL I. · 2017 to 2017
$300k
NCI NIH HHS P30 CA091842NCI NIH HHS R43 CA206796
6 · The paper itself

Abstract

Painful chemotherapy induced peripheral neuropathy (CIPN) is a common complication of chemotherapy with drugs such as taxanes and platinum compounds. Currently, no methods are available for early detection of sensory changes that are associated with painful CIPN, nor are there biomarkers that are specific to painful CIPN. This study aimed to compare Diode Laser fiber type-selective stimulator (DLss), a method to selectively stimulate cutaneous C and Aδ fibers, to traditional quantitative sensory testing (QST) in determining psychophysical differences between patients with painful CIPN and a control group. Sensory testing was performed on the dorsal mid-foot of 20 patients with painful neuropathy after taxane- or platinum-based chemotherapy, and 20 patients who received similar neurotoxic chemotherapy, without painful CIPN. In a multivariable analysis, C-fiber to Aδ fiber detection threshold ratio, measured by DLss, was significantly different between the groups (P <.05). While QST parameters such as warmth detection threshold were different between the groups in univariate analyses, these findings were likely attributable to group differences in patient age and cumulative chemotherapy dose. PERSPECTIVE: In this study, fiber-specific DLss test showed potential in identifying sensory changes that are specific for painful neuropathy, encouraging future testing of this approach as a biomarker for early detection of painful CIPN.

trial registrationThe study was approved by the Washington University Institutional Review Board (#201807162) and registered at ClinicalTrials.gov (NCT03687970).

Indexed as

Antineoplastic AgentsNeurotoxicity SyndromesPeripheral Nervous System DiseasesHumansLasers, SemiconductorPainAntineoplastic AgentsDLss stimulationneuropathic painpainful CIPNperipheral neuropathyQST

Identifiers

PMID34896646
PMCPMC9086082
OpenAlexW4200372091

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.